•  

 

NeuroPharmac Journal

 
Volume 4
 
Autism Spectrum Disorder: Medication Overview
 
FDA-approves the first therapy in 2018 for the Seizures associated with Dravet syndrome
 
Cannabidiol: FDA approved new drug for the Lennox-Gastaut syndrome and Dravet syndrome
 
Caplacizumab: First FDA approved therapy in 2019 for the treatment of adult patients with aquired thrombotic thrombocytopenic purpurea
 
Stiripentol: New approved drug for the Dravet syndrome: Pharmacotherapeutics review

 

NeuroPharmac Journal

 

VOLUME 3

Alzheimer’s disease: Pharmacotherapy of noncognitive symptoms

Alzheimer’s disease: Pharmacotherapy of subjective cognitive decline

Gold standard of Symptomatic treatment in Parkinson disease: Carbidopa/Levodopa

Possible management of non-motor symtoms of Parkinson’s disease

 

 

NeuroPharmac Journal

VOLUME 2

Cerebral Palsy: Basic approach and oral medications

Cerebral Palsy is one of the devastating disorders in medicine. This relatively common problem occurs in babies,
lasts for a lifetime and creates disability ranging from mild to severe. The lesion cannot be cured but the consequences can be minimized with proper treatment. The past decades have witnessed a great deal of change and improvements in the management of Cerebral Palsy Procedures have been modified to be more effective and at the same time minimize the impact of therapy, bracing and surgery on the child’s life. However, this changing and increasing knowledge did not reach many parts of the world.

 

NeuroPharmac Journal

VOLUME 1

Multiple Sclerosis: Promising New Treatment – A Clinical Review

A new McDonald criterion is useful tool for the diagnosis of multiple sclerosis. An initial symptom of multiple sclerosis is weakness in one or more limbs (40%). demyelination
is the main pathophysiological event. Disease-modifying treatment focuses on the long term management of the disease with
the aim to reduce relapse rates, lessen severity, and to slow the progression of disability and cognitive decline. Multiple
sclerosis is not common in Saudi Arabia, it may be fairly prevalent, under-diagnosed and in increasing. there is need to educate
the common community mostly rural community by awareness, attitude and knowledge about multiple sclerosis in order to enhance patient’s adherence to treatment and quality of life.

WELCOME TO NEUROPHARMAC JOURNAL

AIM AND SCOPE OF THE JOURNAL

NeuroPharmac Journal is an open access official peer-reviewed International Journal Publishing three Issues per year and allowing open access to abstracts and full-text. The term “Neuro” is devoted to the promotion of Medical and related disciplines like Clinical research, Nursing research, Physiotherapy research, Occupational therapy research, Pharmaceutical research, Pharmacognosy & Phytochemistry, Pharmacology and Phytopharmacology, Pharmacy Practice, Clinical & Hospital Pharmacy with focus on various neurology updates on neurological disorders and there management.

While the term “Pharmac” is related to research, review and current updates in Pharmaceutical Science field including Pharmaceutics, Pharmacology, Pharmaceutical and Medicinal Chemistry, Pharmacognosy and Phytochemistry, Clinical and Hospital Pharmacy and Pharmaceutical Analysis.

The Journal invites reviews, full length original research articles, concise reports, case study, short-rapid communications of clinical and experimental nature including modern, traditional and epidemiological studies that contributes significantly to the existing knowledge base or open up new frontiers of knowledge in the field of Neurology (medical) and Pharmaceutical Science.

Review articles based primarily on authors own research on internationally important topics will be accepted. Short communications to the editor are also welcome. The primary criteria for acceptance and publication are scientific thoroughness and potential to advance the field of Medical and Pharmaceutical science.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License. (digital archiving policy= LOCKSS)

 

Announcements
  • Welcome to NeuroPharmac Journal

    Articles are Invited for Volume 4, Issue 3 (September-December 2019)